Lutropin alfa is the first and only recombinant human form of luteinizing hormone (LH) developed for use in the stimulation of follicular development. Dose-finding studies revealed a significant dose-dependent increase in the rate of optimal follicular development among women with hypogonadotropic hypogonadism and profound LH deficiency (<1.2 IU/L) who received subcutaneous lutropin alfa 0-225 IU/day plus follitropin alfa. Similarly, in a double-blind, randomized study, the rate of optimal follicular development was significantly higher in women with hypogonadotropic hypogonadism and profound LH deficiency receiving subcutaneous lutropin alfa 75 IU/day plus follitropin alfa than in those receiving placebo plus follitropin alfa. Lutropin alfa with follitropin alfa may also be of benefit in certain subgroups of normogonadotropic women (e.g. those with an inadequate response to prior follitropin alfa monotherapy, those aged >or=35 years, and those with profound LH downregulation or who required excessive exogenous follitropin alfa). However, one study in older women (>or=35 years) did not show any advantage of lutropin alfa supplementation. Once-daily subcutaneous lutropin alfa was generally well tolerated in hypogonadotropic hypogonadal women, with the majority of adverse events being of mild to moderate severity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2165/00003495-200868110-00005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Therapeutic management in women with a diminished ovarian reserve: a systematic review and meta-analysis of randomized controlled trials.
Fertil Steril
September 2024
Department of Public Health, University of Naples Federico II, Naples, Italy.
Article Synopsis
- The clinical management of women with diminished ovarian reserve (DOR) poses challenges, particularly due to inconsistent definitions of DOR across studies.
- This research aims to evaluate various adjuvant treatments for women with DOR based on the POSEIDON criteria, analyzing data from numerous studies published until June 2024.
- The analysis includes 38 randomized controlled trials, identifying testosterone supplementation as a treatment associated with higher live birth rates in women with DOR compared to those who did not receive supplementation.
Vaginal micronized progesterone on preventing luteinizing hormone untimely surge in ART cycles: A prospective proof-of-concept study.
JBRA Assist Reprod
December 2024
Fertipraxis Centro de Reproducao Humana - Rio de Janeiro (RJ), Brazil.
Objective: A new approach to evaluate whether Progestin-Primed Ovarian Stimulation with micronized vaginal progesterone was as effective as using dydrogesterone in suppress LH pulse surge in young women under stimulation in an oocyte donor programme.
Methods: This prospective study included 21 patients aged 19 to 32 years-old stimulated with Elonva® 150, associated or not with Menopur® or Merional® (75 or 150IU) since the beginning of the cycle, plus HMG 150-225IU after the 8th day or just HMG 150-300IU per day. Patients were placed in a PPOS protocol with micronized vaginal progesterone (MVP) 200 mg (Gynpro® Exeltis or Junno Farmoquimica) every 12 hours or dydrogesterone (Duphaston® Abbott) 10 mg every 8 hours from the start of stimulation until the day after the GnRH trigger with Triptorelin 0.
Single and multi-dose pharmacology of recombinant and urinary human chorionic gonadotrophin in men.
Clin Endocrinol (Oxf)
July 2024
ANZAC Research Institute, University of Sydney, Sydney, New South Wales, Australia.
Objective: Human choriogonadotrophin (hCG) treatment of gonadotrophin-deficient infertile men uses hCG of urinary (uhCG) or recombinant (rhCG) origin, but these treatments have not been compared nor are there studies defining rhCG dosing in men.
Design: hCG products were studied in randomized cross-over single-dose studies of standard (Study 1, 1500 IU and 62.5 µg, respectively) or high (Study 2, 5000 IU and 250 µg) dose and a multi-dose population pharmacology study of hCG use.
Comparison of DNA damage in granulosa cells of women undergoing controlled ovarian stimulation in in vitro fertilization protocols with the recombinant human follicle-stimulating hormones Corneumon, Gonal-F, Pergoveris and Puregon: a randomized trial.
Arch Gynecol Obstet
May 2024
Department of Health Sciences, Metropolitan Autonomous University-Iztapalapa Campus, 09340, Mexico City, Mexico.
Purpose: To compare the DNA damage in granulosa cells (GCs) of women undergoing ovarian-stimulated cycles with four widely used recombinant human follicle-stimulating hormones (rhFSH) in in vitro fertilization (IVF) protocols (Corneumon, Gonal-F, Pergoveris and Puregon).
Methods: A randomized trial was carried out at a Mexican hospital. GCs were isolated from 18 women with infertility undergoing assisted reproductive techniques (ART).
Dose accuracy of the follitropin alfa pen injector 2.0, the follitropin alfa:lutropin alfa 2:1 combination pen injector 2.0 and the choriogonadotropin alfa pen injector 1.0 used for fertility treatment.
Expert Opin Drug Deliv
February 2024
Merck Healthcare KGaA, Darmstadt, Germany.
Background: This study aimed to confirm that the incremental dose/clicks system dispenses accurate doses for the Merck family of fertility pen injectors.
Research Design And Methods: Set doses (V) for three dose dial settings (minimum dose [V], midpoint dose [V] and maximum dose [V] for the follitropin alfa, choriogonadotropin alfa [D2 classification: single use/variable dose], and follitropin alfa:lutropin-alfa 2:1 combination pen injectors) or a single V for the choriogonadotropin alfa (D1 classification: single use/single dose) were assessed. Last dose administered by the multi-dose device was assessed for the 900 IU, 450 IU, 300 IU and 150 IU follitropin alfa, and the 900:450 IU, 450:225 IU and 300:150 IU follitropin alfa:lutropin-alfa 2:1 combination pen presentations.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!